BRPI0911518A2 - novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula - Google Patents

novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula

Info

Publication number
BRPI0911518A2
BRPI0911518A2 BRPI0911518A BRPI0911518A BRPI0911518A2 BR PI0911518 A2 BRPI0911518 A2 BR PI0911518A2 BR PI0911518 A BRPI0911518 A BR PI0911518A BR PI0911518 A BRPI0911518 A BR PI0911518A BR PI0911518 A2 BRPI0911518 A2 BR PI0911518A2
Authority
BR
Brazil
Prior art keywords
alzheimer
modulation
disease
treatment
related diseases
Prior art date
Application number
BRPI0911518A
Other languages
English (en)
Inventor
Cohen Daniel
Chumakov Ilya
Guerassimenko Oxana
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of BRPI0911518A2 publication Critical patent/BRPI0911518A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911518A 2008-04-29 2009-04-29 novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula BRPI0911518A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4858508P 2008-04-29 2008-04-29
PCT/EP2009/055207 WO2009133142A1 (en) 2008-04-29 2009-04-29 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response

Publications (1)

Publication Number Publication Date
BRPI0911518A2 true BRPI0911518A2 (pt) 2017-06-13

Family

ID=40873444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911518A BRPI0911518A2 (pt) 2008-04-29 2009-04-29 novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula

Country Status (18)

Country Link
US (1) US8552041B2 (pt)
EP (1) EP2282779B1 (pt)
JP (2) JP5615805B2 (pt)
KR (1) KR101611824B1 (pt)
CN (1) CN102065897B (pt)
AU (1) AU2009242127B2 (pt)
BR (1) BRPI0911518A2 (pt)
CA (1) CA2722314C (pt)
DK (1) DK2282779T3 (pt)
EA (1) EA019571B1 (pt)
ES (1) ES2410930T3 (pt)
IL (1) IL208983A0 (pt)
MX (1) MX2010011880A (pt)
NZ (1) NZ589309A (pt)
PL (1) PL2282779T3 (pt)
PT (1) PT2282779E (pt)
WO (1) WO2009133142A1 (pt)
ZA (1) ZA201008039B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US9493834B2 (en) * 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US8404680B2 (en) * 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
RS53227B (sr) 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
US8701980B2 (en) 2011-10-27 2014-04-22 Veltek Associates, Inc. Air sample tracking system and method
WO2013071119A2 (en) * 2011-11-10 2013-05-16 Genentech, Inc Methods for treating, diagnosing and monitoring alzheimer's disease
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
SI2819664T1 (sl) * 2012-03-01 2017-12-29 Pharnext Novi sestavki za zdravljenje amiotrofične lateralne skleroze
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
AU2014225301B2 (en) * 2013-03-06 2019-05-16 Macquarie University Assay and method for identifying compounds to treat tauopathies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9102645B2 (en) * 2013-03-15 2015-08-11 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
JP2018527016A (ja) * 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
EP3313428A1 (en) * 2015-06-26 2018-05-02 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
WO2017102738A1 (en) 2015-12-13 2017-06-22 Verburgh Kris Methods and compositions to slow down aging in cells and organisms
WO2017171483A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
US10736876B2 (en) 2017-04-24 2020-08-11 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
KR20200014476A (ko) * 2018-08-01 2020-02-11 경북대학교 산학협력단 설폰아마이드 유도체를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
JP2021535180A (ja) * 2018-09-05 2021-12-16 ユニベルシテイト ファン アムステルダム パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用
WO2020150423A1 (en) * 2019-01-16 2020-07-23 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
KR102288613B1 (ko) * 2019-12-05 2021-08-11 대한민국 Atg5를 이용한 경도인지장애 또는 치매의 진단 방법
CN115835862B (zh) * 2020-07-10 2026-01-02 广东横琴新创益生物医药有限公司 治疗阿尔茨海默病的莫达非尼组合
US20230293726A1 (en) * 2020-08-11 2023-09-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for the treatment of wwox associated diseases
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
US20250134895A1 (en) * 2021-08-16 2025-05-01 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN114736959B (zh) * 2022-05-09 2023-09-22 上海市精神卫生中心（上海市心理咨询培训中心） 轻度认知功能损害诊断标志物、试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
EP1006108A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
EP1006112A1 (en) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
KR20040081123A (ko) * 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
ES2334682T3 (es) * 2004-03-05 2010-03-15 Nycomed Gmbh Nuevo uso para inhibidores de pde5.
CA2570245A1 (en) * 2004-07-02 2006-01-12 Warner-Lambert Company Llc Compositions and methods for treating pathological infections
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
DE102005032625A1 (de) * 2005-07-13 2007-01-25 Saiger, Lothar, Dr. Arzneimittel zur Behandlung neuronaler und/oder neurodegenerativer Erkrankungen
JP2007261962A (ja) * 2006-03-27 2007-10-11 Oita Univ 肺高血圧症に有用なエンドセリン受容体拮抗薬。
CN1879604A (zh) * 2006-05-17 2006-12-20 济南帅华医药科技有限公司 一种含抗生素的缓释注射剂及其应用
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
TW200831479A (en) 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.

Also Published As

Publication number Publication date
PL2282779T3 (pl) 2013-08-30
JP5615805B2 (ja) 2014-10-29
JP2014205696A (ja) 2014-10-30
DK2282779T3 (da) 2013-05-27
WO2009133142A1 (en) 2009-11-05
PT2282779E (pt) 2013-05-28
NZ589309A (en) 2012-03-30
EP2282779B1 (en) 2013-03-13
ES2410930T3 (es) 2013-07-03
IL208983A0 (en) 2011-01-31
US20120071483A1 (en) 2012-03-22
CA2722314C (en) 2018-01-02
JP2011518865A (ja) 2011-06-30
EP2282779A1 (en) 2011-02-16
MX2010011880A (es) 2011-05-25
EA201071245A1 (ru) 2011-06-30
ZA201008039B (en) 2011-08-31
US8552041B2 (en) 2013-10-08
CA2722314A1 (en) 2009-11-05
CN102065897A (zh) 2011-05-18
KR20110011628A (ko) 2011-02-08
EA019571B1 (ru) 2014-04-30
CN102065897B (zh) 2013-11-13
AU2009242127A1 (en) 2009-11-05
AU2009242127B2 (en) 2014-03-27
KR101611824B1 (ko) 2016-04-12

Similar Documents

Publication Publication Date Title
BRPI0911520A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
FIC20240036I1 (fi) Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
BRPI0911874A2 (pt) composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
SI2104682T1 (sl) Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
EP2480669A4 (en) TREATMENT OF FILAGGRIN (FLG) ASSOCIATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP2519234A4 (en) ANAPLEROTIC THERAPY FOR MORBUS ALZHEIMER AND BRAIN AGING
EP2340242A4 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
IL208983A0 (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
BRPI1013409A2 (pt) células de tecido de cordão umbilical humano como terapia para doença de alzheimer
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
HUE038785T2 (hu) Hagyományos kínai gyógyszerkészítmény szív- és érrendszeri betegségek kezelésére
EP2182978A4 (en) TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
PT2307000E (pt) Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
PT2422786E (pt) Novas combinações farmacêuticas para o tratamento de doenças respiratórias

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PHARNEXT (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2564 DE 2020-02-27